FDA approves Allergan's migraine tablet ahead of AbbVie merg...

Allergan’s migraine tablet Ubrelvy (ubrogepant) has been approved in the US for the acute treatment of patients with or without aura.

2019: the year of the pharma mega-merger

2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year that changed the landscape of big pharma

BeiGene's Brukinsa fails to beat AbbVie/J&J's Ibrutinib in W...

BeiGene’s Brukinsa (zanubrutinib) has failed to outperform its class rival from Johnson & Johnson/AbbVie in the rare white blood cell cancer Waldenstrom’s macroglublinemia (WM).

Merck buys ArQule and BTK drug for $2.7bn

Merck & Co.

ASH19: AZ’s Calquence throws gauntlet down to Imbruvica

UCB posts more supportive data from Humira rival bimekizumab

There’s a whole gang of pharma companies queueing up to steal market share from AbbVie’s mega-blockbuster Humira, and UCB’s contender bimekizumab is shaping up for a challenge with another